

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 May 2002 (16.05.2002)

PCT

(10) International Publication Number
WO 02/38184 A1

(51) International Patent Classification⁷: **A61K 47/34**,
A61P 7/02

(21) International Application Number: PCT/SE01/02470

(22) International Filing Date:
7 November 2001 (07.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0027375.5 9 November 2000 (09.11.2000) GB
0104751.3 27 February 2001 (27.02.2001) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): AS-TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BATEMAN, Nicola [GB/GB]; AstraZeneca R & D Alderley, Mereside, Alderley Park, Macclesfield SK10 4TF Cheshire (GB). CAHILL, Julie [GB/GB]; AstraZeneca, Silk Road Business Part, Charter Way, Macclesfield SK10 2NA Cheshire (GB).

Published:

— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ORAL PHARMACEUTICAL COMPOSITION CONTAINING A BLOCK COPOLYMER

(57) Abstract: The invention relates to oral pharmaceutical compositions that comprise a water miscible micelle forming block copolymer and a compound. The copolymer can be a diblock copolymer of formula AB or BA. The copolymer could also be triblock copolymer of formula ABA or BAB, or a multiblock copolymer having repeating BA or AB units of formula A(BA)_n or B(AB)_n, where n is an integer. The A-block may be poly(L-lactide) or poly(D-, L-, or DL-lactic acid) and the B-block a polyethylene glycol.

WO 02/38184 A1

5

ORAL PHARMACEUTICAL COMPOSITION CONTAINING A BLOCK COPOLYMER

The invention relates to oral pharmaceutical compositions which comprise a water miscible micelle forming block copolymer (hereinafter called "the copolymer") and a compound. The copolymer can be a diblock copolymer of formula AB or BA. However the
10 copolymer could also be a triblock copolymer of formula ABA or BAB. The copolymer could also be a multiblock copolymer having repeating BA or AB units of formula A(BA)_n or B(AB)_n, where n is an integer and wherein

A is selected from a group consisting of

- poly D-, L-, DL-lactic acid,
- 15 poly D-, L-, DL-lactide,
- poly-glycolic acid,
- polyglycolide,
- polylactide-co-glycolide,
- poly-ε-caprolactone, and
- 20 poly(3-hydroxybutyric acid); and

B is selected from a group of hydrophilic polymers consisting of

- polyvinylalcohol,
- polyvinylpyrrolidone,
- polyethylene oxide, and
- 25 polyethylene glycol; or the hydrophilic polymer B may itself be a copolymer, for example a polyoxyethylene/polyoxypropylene block copolymer of the type known as Pluronic or synperonics.

Copolymers of the type described above are known, see for example US 4,942,035, USA 745,160, US4,526,938 or EP0,166,596,B1. Specifically these types of polymers are
30 used in the formulation of parenteral compositions of drugs due to the ability of the copolymer to provide release of the drug over a prolonged period, several days. Previously it has not been thought that these polymers were suitable for oral administration due to the prolonged periods of release of drug, which would be unsuitable for achieving ideal oral adsorption of drug.

We have surprisingly found that such polymers are indeed suitable for oral
35 administration of compounds and are particularly suitable for formulation to produce oral compositions of compounds with low aqueous solubility (less than 0.1mg/ml at the site of

5 absorption). Whilst not wishing to be bound by theory we believe that these copolymers act by a combination of dissolution enhancement and prevention of precipitation and thus can greatly increase levels of drug absorption after oral administration.

In particular the polymers are particularly good with compounds which have significantly lower solubility in the pH conditions encountered at the site of adsorption, typically the duodenum, ileum or colon, than in the stomach. Typically these are basic
10 compounds which are more soluble in the acidic stomach than the more alkaline conditions found in the site of absorption.

Compounds which have low aqueous solubility or basic compounds may produce problems in their absorption possibly producing unacceptable levels of variability in
15 absorption between patient and between dose.

A common factor which may affect the absorption of a drug when administered orally is the changing pH experienced by the drug as it passes through the GI tract. Typically a drug may be absorbed in any number of the following sites when administered orally; cheek lining, stomach, duodenum, ileum and colon. The pH may be different at each site of adsorption with
20 the pH significantly different from the stomach (pH 1-3.5) to the small intestine (pH 4-8). The solubility of the drug may vary with pH leading to the possibility of the drug coming out of solution as it passes through the GI tract. Particular difficulties exist where the drug is dissolved and the solubility decreases in the pH environment found at the site of adsorption. This leads to possible low absorption and variable adsorption between doses and different
25 patients. For example we have found with the drug 1-(6-chloronaphth-2-ylsulfonyl)-4-[4-(4-pyridyl)benzoyl] piperazine (hereinafter referred to as Compound 1) is soluble within the acidic pH of the stomach, but is not adsorbed from this area, but has low solubility in the duodenum, ileum and colon which are the main sites of adsorption.

Compound 1 possesses Factor Xa inhibitory activity at concentrations which do not
30 inhibit, or which inhibit to a lesser extent, the enzyme thrombin which is also a member of the blood coagulation enzymatic cascade.

Compound 1 is disclosed as Example 3 of WO9957113.

Compound 1 possesses activity in the treatment or prevention of a variety of medical disorders where anticoagulant therapy is indicated, for example in the treatment or prevention
35 of thrombotic conditions such as coronary artery and cerebro-vascular disease. Further examples of such medical disorders include various cardiovascular and cerebrovascular

5 conditions such as myocardial infarction, the formation of atherosclerotic plaques, venous or
arterial thrombosis, coagulation syndromes, vascular injury (including reocclusion and
restenosis following angioplasty and coronary artery bypass surgery, thrombus formation after
the application of blood vessel operative techniques or after general surgery such as hip
10 replacement surgery, the introduction of artificial heart valves or on the recirculation of
blood), cerebral infarction, cerebral thrombosis, stroke, cerebral embolism, pulmonary
embolism, ischaemia and angina (including unstable angina).

Standard tablet formulations of compound 1 may not be satisfactory due to the above
reasons and have lead to poor oral bioavailability and most importantly high variability in
adsorption. Variability is of most concern with any drug affecting the clotting cascade, care is
15 needed since complete blockage of the clotting cascade is an unwanted side effect. On the
other hand low exposure levels to the compound will not lead to any therapeutic benefit.
Therefore, good oral bioavailability is required and, particularly, low variability.

We have found with the polymers described above that they act as solubilising
enhancers as well as precipitation inhibitors, also the polymers are self dispersing, water
20 miscible and micelle forming.

We present as a feature of the invention an oral pharmaceutical composition
comprising a compound and water miscible micelle forming block copolymer (hereinafter
called "the copolymer"). Ideally the copolymer is a diblock copolymer of formula AB or BA.
However the copolymer could also be a triblock copolymer of formula ABA or BAB. The
25 copolymer could also be a multiblock copolymer having repeating BA or AB units of formula
 $A(BA)_n$ or $B(AB)_n$, where n is an integer (preferably the copolymer is a diblock copolymer of
formula AB or BA) and wherein

A is selected from a group consisting of

poly D-, L-, DL-lactic acid,

30 poly D-, L-, DL-lactide,

poly-glycolic acid,

polyglycolide,

polylactide-co-glycolide,

poly-ε-caprolactone, and

35 poly(3-hydroxybutyric acid); and

B is selected from a group of hydrophilic polymers consisting of

5 polyvinylalcohol,
polyvinylpyrrolidone,
polyethylene oxide, and
polyethylene glycol; or the hydrophilic polymer B may itself be a copolymer, for example a
polyoxyethylene/polyoxypropylene block copolymer of the type known as Pluronics or
10 synperonics.

A further feature of the invention is the use of water miscible micelle forming block
copolymer in improving the oral bioavailability and/or variability of adsorption of a
compound. Ideally the copolymer is a diblock copolymer of formula AB or BA. However the
copolymer could also be a triblock copolymer of formula ABA or BAB. The copolymer
15 could also be a multiblock copolymer having repeating BA or AB units of formula A(BA)_n
or B(AB)_n, where n is an integer (preferably the copolymer is a diblock copolymer of formula
AB or BA) and wherein

A is selected from a group consisting of

poly D-, L-, DL-lactic acid,
20 poly D-, L-, DL-lactide,
poly-glycolic acid,
polyglycolide,
polylactide-co-glycolide (PLGA),
poly-ε-caprolactone, and
25 poly(3-hydroxybutyric acid); and

B is selected from a group of hydrophilic polymers consisting of

polyvinylalcohol,
polyvinylpyrrolidone,
polyethylene oxide, and
30 polyethylene glycol; or the hydrophilic polymer B may itself be a copolymer, for example a
polyoxyethylene/polyoxypropylene block copolymer of the type known as Pluronics or
synperonics;
in improving the oral bioavailability and/or variability of adsorption of a compound.

The compound is an organic molecule of MW < 800, the formulation working best
35 with compounds which are poorly aqueous soluble and also with a compound which is basic,
adsorbed after administration in the small intestine and in which such compound has

5 significantly lower solubility in the pH conditions found at the site of adsorption than in the stomach.

Preferably the copolymer is a diblock copolymer of formula AB or BA or triblock copolymer of formula ABA or BAB. More preferably the copolymer is a diblock copolymer of formula AB or BA. Preferably the A block segment of the block copolymer, is a poly-(D-,
10 ,L- or DL-lactic acid) or poly (D-,L- or DL-lactide). Preferably the Mw is between 500 Da and 5000 Da. More preferably between 1000 Da and 3000 Da and even more preferably between 1500 Da and 2000 Da. Preferably the B block segment of the copolymer is a polyethylene glycol, preferably methoxy-polyethylene glycol. Preferably the Mw is between 500 Da and 10,000 Daltons, more preferably between 1,000 Da and 5000 Da.

15 The most preferred copolymer is an AB diblock copolymer where A is a poly-(D-,L- or DL-lactic acid) or poly (D-,L- or DL-lactide) of Mw 2000 Da and B is a methoxypolyethylene glycol of Mw 2000Da.

The polymer may be judged to be micelle forming by a person skilled in the art by determination of the Critical Micelle Concentration (cmc). The formation of micelles of the
20 copolymer in an aqueous environment is supported by the detection of the cmc, which can be measured using the Wilhelmy plate method. (S.A Hagan, A.G.A Coombes, M.C. Garnett, S.E. Dunn, M.C. Davies, L. Illum and S.S. Davis, Langmuir 1996, 12, 2153-2161)

Methods for the preparation of the polymers used are described in US 4,942,035 and US4,526,938 or EP0,166,596,B1 Zhu. K.J, Lin. X.Z and Yang S.L. Preparation,
25 characterisation and properties of polylactide (PLA)-poly(ethyleneglycol) (PEG) copolymers. J Appl. Polym. Sci., 39(1990)

By the use of the term "significantly lower solubility in the pH conditions found at the site of adsorption than in the stomach" we mean that the solubility of the compound is at least 10x more soluble in the pH conditions found in the stomach (pH1-2) than the pH conditions
30 found in the small intestine, (pH6-9), preferably 20x, 30x, 40x, 50x and X100

We have found in *in vitro* tests that the maximum supersaturated concentration of Compound 1 is improved by 4-10 times by use of the polymers described above.

A preferred ratio of copolymer to compound is from 10:1 to 0.25:1. Preferably 5:1 to 1:1

35 A preferred compound is Compound 1, 1-(5-chloroindol-2-ylsulfonyl)-4-[4-(4-pyridyl)benzoyl] piperazine (hereinafter called Compound 2) and 1-(5-chloroindol-2-

- 5 ylsulfonyl)-4-[4-(1-imidazolyl)benzoyl] piperazine (hereinafter called Compound 3).
Compound 2 and Compound 3 are disclosed in Examples 3 and 6 respectively of
WO9957113. Compound 2 and 3 like Compound 1 are Factor Xa inhibitors.

The composition may contain from 0.01mg to 1g of compound. Additional excipients may be included in the composition.

- 10 Typically the compound will be present in an amount within the range of 1 to 80% ,
and preferably from 1 to 50% (especially 2 to 15% 2 to 20%) by weight of the composition.

- The composition may be made by admixture of the compound and polymer, preferably by cryo-grinding the polymer and mixing with the compound, compression then may be used. Preferred methods for preparing a composition is as a solid dispersion, such techniques are
15 known in the art and typically comprise the steps of dissolving the compound and the polymer in a common solvent and evaporating the solvent. Methods for evaporating the solvent include rotary evaporation, spray drying with appropriate excipients, lyophilization and thin film evaporation. Other techniques may be used such as solvent controlled precipitation, pH controlled precipitation, supercritical fluid technology and hot melt extrusion. To aid the
20 process the melt may be extruded with any necessary additional excipient such as a plasticiser, including supercritical fluids. With hot melt extrusion the melt may be extruded or filled directly into capsules

- When referring to a solid dispersion we do not exclude the possibility that a proportion of the compound may be dissolved within the polymer used, the exact proportion, if any, will
25 depend upon the physical properties of the compound and the polymer selected.

Conventional excipients which may be added include preservatives, stabilisers, anti-oxidants, silica flow conditioners, antiadherents or glidants.

The invention is illustrated below by the following non-limiting examples.

30 **Preparation of solid dispersion**

For a 1:5 ratio

- 0.5g of drug (Compound 1) and 2.5g of polymer are weighed directly into a 250ml round bottom flask and dissolved in 63ml of methanol/dichloromethane (50:50). The solvent was removed on the rotary evaporator. The formulation was placed in a vacuum oven and dried
35 under high vacuum at 40°C for 48hours.

Weights and volumes for other ratio's are pro-rata to the above formulation.

5

Solubility Measurements**Solubility Compound 1**

| | | |
|----|-------|----------|
| | Water | <5ug/ml |
| 10 | pH1.2 | 250ug/ml |
| | pH6.8 | 2ug/ml |

In vitro dissolution of solid dispersions**pH shift dissolution method**

- 15 The formulations were weighed into hard gelatin capsules (equivalent to 25mg drug) and dissolved in 500ml 0.1N HCl for one hour at 37°C (paddle speed 100rpm). A 5ml sample was taken at 55minutes and the media replaced. After one hour 10ml of a 2.5M KH_2PO_4 / 16.72% (w/v) NaOH solution was added to the HCl to shift the pH to 6.5. 5ml samples were then removed with a plastic syringe at 5, 15, 30, 45 and 60 minutes and media
- 20 replaced after every sampling time point. Each sample was centrifuged (14,000rpm) at ambient temperature for 15 minutes and then analysed by HPLC using the following conditions:

- | | | |
|----|-----------------------|-------------------------------------|
| | Eluent: | 40% ACN / 60% water / 0.2% TFA |
| 25 | column: | 25cm HIRPB 4.6mm i.d.. (with guard) |
| | detection wavelength: | 236nm |
| | flow rate: | 1.5ml/min |
| | temperature: | ambient |
| | injection volume: | 80µl |
| 30 | retention time: | approximately 6 minutes |

pH 6.5 dissolution method

- The formulations were weighed into hard gelatin capsules (equivalent to 25mg drug) and dissolved in media comprising of 500ml 0.1N HCl and 10ml of a 2.5M KH_2PO_4 / 16.72% (w/v) NaOH solution for one hour at 37°C (paddle speed 100rpm). 5ml samples were
- 35 then removed with a plastic syringe at 5, 10, 20, 30, 45 and 60 minutes and media replaced after every sampling time point. Each sample was centrifuged (14,000rpm) at ambient

5 temperature for 15 minutes and then analysed by HPLC using the same conditions as the pH shift method.

Figure 1 shows the release profile of a solid dispersion of Compound 1 with a PLA:PEG AB block copolymer and Pluronic polymers using the pH shift dissolution method. A conventional suspension of Compound 1 was included for comparison. This figure
10 demonstrates that the PLA:PEG polymer is the optimal solid dispersion matrix material since the highest levels of supersaturation are attained with this polymer. The solid dispersions made with Pluronic F-68 and F-127 do not provide any great advantage over a conventional suspension of Compound 1. Similarly to the conventional suspension, on shifting to the higher pH, the Pluronic formulations are not capable of maintaining supersaturated levels.

15 Figure 2 shows the release profile of two PLA:PEG AB block copolymer formulations of Compound 1 (SD is a solid dispersion and mix is an admixture) in the pH 6.5 dissolution test. A conventional suspension of Compound 1 was included for comparison. This figure demonstrates that in the absence of any prior formulation, the PLA:PEG polymer is capable of enhancing the dissolution of Compound 1 (admixture). This may be as a result of the polymer
20 solubilising the compound.

Figure 3 shows the release profile of two PLA:PEG AB block copolymer formulations of Compound 1 (SD is a solid dispersion and mix is an admixture) in the pH shift dissolution test. A conventional suspension of Compound 1 was included for comparison. This figure demonstrates that the PLA:PEG polymer is capable of maintaining supersaturated levels of the
25 compound 1 in both the formulated and non-formulated state (i.e. SD or mix). Figures 2 and 3 demonstrate that the PLA:PEG's could be acting by a combination of solubilisation and inhibition of precipitation.

5

Claims

1. An oral pharmaceutical composition comprising a compound and a diblock copolymer of formula AB or BA or a triblock copolymer of formula ABA or BAB or a multiblock copolymer having repeating BA or AB units of formula $A(BA)_n$ or $B(AB)_n$, where n is an integer and wherein

A is selected from a group consisting of

- poly D-, L-, DL-lactic acid,
poly D-, L-, DL-lactide,
15 poly-glycolic acid,
polyglycolide,
polylactide-co-glycolide,
poly-ε-caprolactone, and
poly(3-hydroxybutyric acid); and

- 20 B is selected from a group of hydrophilic polymers consisting of

- polyvinylalcohol,
polyvinylpyrrolidone,
polyethylene oxide, and
polyethylene glycol; or the hydrophilic polymer B may itself be a copolymer, for example a
25 polyoxyethylene/polyoxypropylene block copolymer of the type known as Pluronics or
synperonics.

2. Use of a water miscible micelle forming diblock copolymer of formula AB or BA or a triblock copolymer of formula ABA or BAB or a multiblock copolymer having repeating BA or AB units of formula $A(BA)_n$ or $B(AB)_n$, where n is an integer and wherein

A is selected from a group consisting of

- poly D-, L-, DL-lactic acid,
poly D-, L-, DL-lactide,
poly-glycolic acid,
35 polyglycolide,
polylactide-co-glycolide (PLGA),

- 5 poly-ε-caprolactone, and
poly(3-hydroxybutyric acid); and
B is selected from a group of hydrophilic polymers consisting of
polyvinylalcohol,
polyvinylpyrrolidone,
10 polyethylene oxide, and
polyethylene glycol; or the hydrophilic polymer B may itself be a copolymer, for example a
polyoxyethylene/polyoxypropylene block copolymer of the type known as Pluronic or
synperonics;
in improving the oral bioavailability and/or variability of adsorption of a compound.
- 15
3. An oral pharmaceutical composition as claimed in claim 1 or use of a water miscible
micelle forming copolymer as claimed in claim 2 wherein the A block segment of the
copolymer is a poly-(D-,L- or DL-lactic acid) or poly (D-,L- or DL-lactide).
- 20 4. An oral pharmaceutical composition as claimed in claim 3 or use of a water miscible
micelle forming copolymer as claimed in claim 3 wherein the Mw of the A polymer is
between 500 Da and 5,000 Da.
5. An oral pharmaceutical composition as claimed in claim 4 or use of a water miscible
25 micelle forming copolymer as claimed in claim 4 wherein the Mw of the A polymer is
between 1000 Da and 3000 Da.
6. An oral pharmaceutical composition as claimed in claim 5 or use of a water miscible
micelle forming copolymer as claimed in claim 5 wherein the Mw of the A polymer is
30 between 1300 Da and 2200 Da.
7. An oral pharmaceutical composition as claimed in claim 6 or use of a water miscible
micelle forming copolymer as claimed in claim 6 wherein the Mw of the A polymer is 2000
Da.

- 5 8. An oral pharmaceutical composition as claimed in any one of claims 1 or 3 to 7 or use
of a water miscible micelle forming copolymer as claimed in any claim from 2 to 7 wherein
the B block segment of the copolymer is a polyethylene glycol.
9. An oral pharmaceutical composition as claimed in claim 8 or use of a water miscible
10 micelle forming copolymer as claimed in claim 8 wherein the B block segment of the
copolymer is methoxy-polyethylene glycol.
10. An oral pharmaceutical composition as claimed in claim 8 or 9 or use of a water
miscible micelle forming copolymer as claimed in claim 8 or 9 wherein the Mw of the B
15 polymer is between 500 Da and 10,000 Da.
11. An oral pharmaceutical composition as claimed in claim 10 or use of a water miscible
micelle forming copolymer as claimed in claim 10 wherein the Mw of the B polymer is
between 1,000 Da and 5000 Da.
- 20 12. An oral pharmaceutical composition as claimed in any one of claims 1, or 3 to 11 or
use of a water miscible micelle forming copolymer as claimed in any one of claims 2 to 11
wherein the copolymer is a diblock copolymer of formula AB or BA.
- 25 13. An oral pharmaceutical composition as claimed in any one of claims 1 or 3 to 11 or
use of a water miscible micelle forming copolymer as claimed in any one of claims 2 to 11
wherein the copolymer is a triblock copolymer of formula ABA or BAB.
14. An oral pharmaceutical composition comprising a compound and a diblock copolymer
30 of formula AB or BA wherein A is a polyL-lactide of Mw of 2000 Da and B is a polyethylene
glycol of Mw of 2000 Da.
15. An oral pharmaceutical composition comprising a compound and a diblock copolymer
of formula AB or BA wherein A is a poly-(D-,L- or DL-lactic acid) or poly (D-,L- or DL-
35 lactide) of Mw 2000 Da and B is a methoxypolyethylene glycol of Mw 2000Da.

- 5 16. An oral pharmaceutical composition as claimed in any one of claims 1 or 3 to 15 wherein the compound is selected from 1-(6-chloronaphth-2-ylsulfonyl)-4-[4-(4-pyridyl)benzoyl] piperazine, 1-(5-chloroindol-2-ylsulfonyl)-4-[4-(4-pyridyl)benzoyl] piperazine and 1-(5-chloroindol-2-ylsulfonyl)-4-[4-(1-imidazolyl)benzoyl] piperazine.
- 10 17. An oral pharmaceutical composition as claimed in any one of claims 1 or 3 to 15 wherein the ratio of copolymer to compound is from 10:1 to 0.25:1.
18. An oral pharmaceutical composition as claimed in any one of claims 1 or 3 to 15 wherein the composition comprises from 0.01 mg to 1 mg of compound.

5




Figure 1

10

5




Figure 2

10

5




Figure 3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/02470

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 47/34, A61P 7/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI-DATA, EPO-INTERNAL, CA DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| X | WO 9918142 A1 (MACROMED, INC.), 15 April 1999 (15.04.99), see abstract, page 24 and claim no. 27 -- | 1-18 |
| X | WO 0019996 A1 (KWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY), 13 April 2000 (13.04.00), page 7; page 9, claims 1,4 and 10 -- | 1-18 |
| X | US 5665428 A (CHA ET AL), 9 Sept 1997 (09.09.97), see abstract, column 7-8, table 1 and examples 1 and 6 -- | 1-18 |
| A | WO 9957113 A1 (ZENECA LIMITED), 11 November 1999 (11.11.99), see page 1 and examples 3 and 6 -- | 1-18 |

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

4 March 2002

Date of mailing of the international search report

05-03-2002

Name and mailing address of the ISA:

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Ingrid Fallenius/BS

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

28/01/02

International application No.

PCT/SE 01/02470

| Patent document cited in search report | | | Publication date | Patent family member(s) | | Publication date |
|---|---------|----|---------------------|----------------------------|-------------|---------------------|
| WO | 9918142 | A1 | 15/04/99 | AU | 736812 B | 02/08/01 |
| | | | | AU | 1098300 A | 17/04/00 |
| | | | | AU | 9678098 A | 27/04/99 |
| | | | | BR | 9815239 A | 11/12/01 |
| | | | | BR | 9914258 A | 03/07/01 |
| | | | | CN | 1282345 T | 31/01/01 |
| | | | | CN | 1324374 T | 28/11/01 |
| | | | | EP | 1034207 A | 13/09/00 |
| | | | | EP | 1141079 A | 10/10/01 |
| | | | | NO | 20011639 A | 30/03/01 |
| | | | | TR | 200000900 T | 00/00/00 |
| | | | | US | 6117949 A | 12/09/00 |
| | | | | US | 6201072 B | 13/03/01 |
| | | | | WO | 0018821 A | 06/04/00 |
| | | | | US | 6004573 A | 21/12/99 |
| | | | | ZA | 9809009 A | 14/06/99 |
| ----- | | | | | | |
| WO- | 0019996 | A1 | 13/04/00 | AU | 6008499 A | 26/04/00 |
| ----- | | | | | | |
| US | 5665428 | A | 09/09/97 | AU | 7479796 A | 15/05/97 |
| | | | | CA | 2235602 A | 01/05/97 |
| | | | | EP | 0857081 A | 12/08/98 |
| | | | | JP | 11515016 T | 21/12/99 |
| | | | | WO | 9715389 A | 01/05/97 |
| ----- | | | | | | |
| WO | 9957113 | A1 | 11/11/99 | AU | 3620699 A | 23/11/99 |
| | | | | BR | 9910179 A | 09/01/01 |
| | | | | CN | 1308631 T | 15/08/01 |
| | | | | EP | 1082321 A | 14/03/01 |
| | | | | GB | 9809351 D | 00/00/00 |
| | | | | HU | 0101712 A | 28/11/01 |
| | | | | NO | 20005497 A | 21/12/00 |
| | | | | PL | 343706 A | 27/08/01 |
| | | | | SK | 16512000 A | 10/05/01 |
| | | | | AU | 6216699 A | 01/05/00 |
| | | | | EP | 1119636 A | 01/08/01 |
| | | | | GB | 9903337 D | 00/00/00 |